Eton Pharmaceuticals Announces FDA Approval of ZONISADE™ (Zonisamide Oral Suspension)
18 juil. 2022 07h05 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., July 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces Sale of Hospital Products
24 juin 2022 07h30 HE
|
Eton Pharmaceuticals
Eton sold its rights in Biorphen®, Rezipres®, and Cysteine Hydrochloride products for total payments of up to $50 millionGoing forward, Eton’s commercial portfolio will exclusively focus on products...
Eton Pharmaceuticals Reports First Quarter 2022 Financial Results
12 mai 2022 16h02 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., May 12, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022
03 mai 2022 16h02 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., May 03, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Appoints James Gruber as Chief Financial Officer
11 avr. 2022 16h01 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces FDA Approval of Cysteine Hydrochloride Injection
11 avr. 2022 07h30 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., April 11, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Fourth Quarter 2021 Financial Results
16 mars 2022 16h02 HE
|
Eton Pharmaceuticals
Fourth Quarter 2021 Revenue of $6.1 millionFourth Quarter 2021 Net Income of $1.0 million and EPS of $0.04 DEER PARK, Ill., March 16, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq:...
Eton Pharmaceuticals and XGen Pharmaceuticals DJB Announce Commercial Launch of Rezipres® (ephedrine hydrochloride), a Ready-to-Use Formulation of Injectable Ephedrine (4.7 mg/mL)
14 mars 2022 07h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., March 14, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON) and XGen Pharmaceuticals DJB, Inc. today announced the commercial availability of Rezipres® (ephedrine...
Eton Pharmaceuticals to Report Fourth Quarter 2021 Financial Results on Wednesday, March 16, 2022
08 mars 2022 08h00 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals and ANI Pharmaceuticals Announce Commercial Availability of Carglumic Acid Tablets, the First and Only FDA-Approved Generic Version of Carbaglu® (carglumic acid)
20 déc. 2021 07h30 HE
|
Eton Pharmaceuticals
Product is now available exclusively through Anovo specialty pharmacyProduct is stable at room temperature while Carbaglu® requires refrigerationEton Cares patient support program will offer $0...